SpineGuard reports financial results for the first half of 2024 Page 1

Regulatory news:

SpineGuard (FR0011464452 – ALSGD), an innovative company using its local conductivity sensing technology DSG (Dynamic Surgical Guidance) to secure and optimize bone implant placement, today announces its financial results for the six months ended June 30, 2024, as approved by the Board of Directors on September 11, 2024.

Pierre Jérôme, co-founder, chairman and CEO of SpineGuard, explained: “The results of the first half of 2024 are in line with our business plan. We started the year with a return to growth in the first quarter of 2024, followed by an acceleration in the second quarter, driven by our strengthened American commercial structure and our partnership with Omnia Medical. As a result, we achieved double-digit growth in the first half at constant exchange rate and maintained gross margin at close to 80%. Net loss improved by almost 20% and EBITDA by over 30%. In terms of revenue, the gradual launch of new devices with DSG technology should significantly help sustain growth in the coming quarters. At the same time, we are working to obtain approval for the full range of PediGuard products in China and forge new strategic partnerships to complete our financing and successfully launch the dental and robotic applications of our technology. By achieving these goals and outlooks, we confirm our ability to break even during 2026.”